Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration.

导出 LinkOut

翻译打印收藏纠错

作者： Jochen,Dutzmann ^[1] ; Lena Marie,Bode ^[2] ; Katrin,Kalies ^[1] ; Laura,Korte ^[2] ; Kai,Knöpp ^[1] ; Frederik Julius,Kloss ^[2] ; Mirja,Sirisko ^[2] ; Claudia,Pilowski ^[1] ; Susanne,Koch ^[1] ; Heiko,Schenk ^[3] ; Jan-Marcus,Daniel ^[1] ; Johann,Bauersachs ^[2] ; Daniel G,Sedding ^[2]

作者单位： Mid-German Heart Center, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. ^[1] Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany. ^[2] Department of Nephrology and Hypertension, Hannover Medical School, Hanover, Germany. ^[3]

关键词 SGLT2 diabetes neointima formation restenosis vascular remodeling

DOI 10.3389/fcvm.2022.956041

PMID 36017090

发布时间 2022-08-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in cardiovascular medicine

2022年9卷

956041页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration.

Frontiers in cardiovascular medicine

相似文献

Frontiers in cardiovascular medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration.

Frontiers in cardiovascular medicine

相似文献

Frontiers in cardiovascular medicine

相关期刊

检索历史清除